Drug intelligence / Profile preview

ANXA7 siRNA

Development stage
Unknown
Lead developer
University of Alabama at Birmingham
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intrathecal
01

Overview

ANXA7 siRNA is a small interfering RNA (siRNA) designed to silence the expression of Annexin A7 (ANXA7), a member of the annexin family of calcium-dependent phospholipid-binding proteins. In the context of glioblastoma multiforme (GBM), ANXA7 isoforms play distinct roles in the endosomal trafficking of the epidermal growth factor receptor (EGFR). The ANXA7-I1 isoform is specifically involved in directing EGFR toward lysosomal degradation. By utilizing ANXA7 siRNA to knock down total ANXA7 expression, researchers have demonstrated that the loss of this protein impairs EGFR sorting to lysosomes and promotes receptor recycling, leading to sustained oncogenic signaling. This agent is primarily used as a research tool in preclinical studies to investigate the molecular mechanisms of receptor tyrosine kinase regulation and alternative splicing in cancer.

Other names
Annexin A7 siRNAsiRNA targeting ANXA7
02

Targets

ANXA7Innate immune RNA sensors

Beyond the preview

Go deeper on ANXA7 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANXA7 siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call